Randomized, double-blind, crossover study of the adhesiveness of two formulations of rotigotine transdermal patch in patients with Parkinson’s disease
- 20 February 2018
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 34 (7) , 1293-1299
Abstract
Objective: In patch-based transdermal drug delivery, adhesiveness is critical for safe and effective treatment, especially in Parkinson's disease (PD) where excessive sweating is common. This study compared the adhesiveness of two transdermal patch formulations of rotigotine (improved room temperature-stable [PR2.3.1/Treatment A] and intermediate cold storage product [PR2.1.1/Treatment B]), using the largest patch size (40cm(2)).Methods: PD0018 (NCT02230904) was a multicenter, randomized, double-blind, crossover study. PD patients received Treatments A and B in randomized order for 2 days each. Patch adhesiveness was measured immediately after patch application and 24 hours thereafter (before removal). Primary variable: change in average investigator-rated adhesiveness score between treatments, per modified European Medicines Agency scale (EMA/CHMP/QWP/911254/2011, 2012).Results: Fifty-seven patients were randomized; 56 patients completed the study. Five patients were excluded from analysis for accidental unblinding. Treatment A had better average adhesiveness score (meanSD Treatment A - Treatment B: 1.115 +/- 1.635). A higher percentage of patients on both days had patch adhesiveness 95% at 24 hours for Treatment A (first day: 65.4%, second day: 71.2%) vs. Treatment B (46.2%, 36.5%), and were satisfied with patch adhesiveness of Treatment A (first day: 75.0%, second day: 73.1%) vs. Treatment B (65.4%, 59.6%). Average patch-wear duration was similar between formulations (23.761 hours vs. 23.495 hours per patch). Both formulations were well tolerated with no new safety observations.Conclusion: Results indicated greater adhesiveness for the improved room temperature-stable formulation (PR2.3.1) vs. intermediate cold storage product (PR2.1.1) using the largest patch-size, with comparable safety and skin tolerability.Keywords
This publication has 7 references indexed in Scilit:
- Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?Ageing Research Reviews, 2014
- Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulationsCurrent Medical Research and Opinion, 2013
- Gastric Dysfunction in Parkinson’s Disease2012
- Steady-State Plasma Concentration Profile of Transdermal Rotigotine: An Integrated Analysis of Three, Open-Label, Randomized, Phase I Multiple Dose StudiesClinical Therapeutics, 2012
- Adhesive properties: a critical issue in transdermal patch developmentExpert Opinion on Drug Delivery, 2011
- The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s diseaseNaunyn-Schmiedeberg's Archives of Pharmacology, 2008
- Sweating dysfunction in Parkinson's diseaseMovement Disorders, 2003